ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis
Journal
Clinical Cancer Research
ISSN
1078-0432
1557-3265
Publisher
American Association for Cancer Research
Date Issued
2023
Author(s)
Arrieta, Víctor A.
Duerinck, Johnny
Burdett, Kirsten B.
Habashy, Karl J.
Geens, Wietse
Gould, Andrew
Schwarze, Julia K.
Dmello, Crismita
Kwang-Soo Kim
Saganty, Ruth
Li Chen
Moscona-Nissan, Alberto
Mccord, Matthew
Lee-Chang, Catalina
Craig M. Horbinski
Hui Zhang
Stupp, Roger
Bart Neyns
Sonabend, Adam M.
Type
text::journal::journal article
Abstract
Purpose: Evidence suggests that MAPK pathway activation, as measured by ERK1/2 phosphorylation (p-ERK), predicts overall survival (OS) in patients with recurrent glioblastoma receiving anti-PD-1 therapy. We aimed to validate these findings in independent cohorts. Experimental Design: In a 24-patient clinical trial on recurrent glioblastoma and high-grade gliomas, we examined the link between p-ERK levels and OS. Patients received intravenous nivolumab, followed by maximal safe resection and an intracerebral injection of either ipilimumab alone or combined with nivolumab. Biweekly adjuvant nivolumab was then administered up to five times (NCT03233152). Using REporting recommendations for tumor MARKER prognostic studies (REMARK) criteria, we conducted independent analyses for p-ERK quantification and statistical evaluations. Additional comparative analysis included prior cohorts, totaling 65 patients. Cox proportional hazards models and meta-analysis were employed to assess p-ERK as a predictive biomarker after immunotherapy. ©American Association for Cancer Research
How to cite
Arrieta VA, Duerinck J, Burdett KB, Habashy KJ, Geens W, Gould A, Schwarze JK, Dmello C, Kim KS, Saganty R, Chen L, Moscona A, McCord M, Lee-Chang C, Horbinski CM, Zhang H, Stupp R, Neyns B, Sonabend AM. ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis. Clin Cancer Res. 2024 Jan 17;30(2):379-388. doi: 10.1158/1078-0432.CCR-23-1889. PMID: 37939133; PMCID: PMC10842826.